Lee Greene Hicks, MD

Medical Oncology
Gender: Male
4.9 of 5 (219 Ratings)
Accepting New Patients

Clinical Focus

Cancerous tumors, Gastrointestinal Cancers

Practice Locations

Baptist Health Medical Group Hematology & Oncology
1700 Nicholasville Road, Suite 1100
Lexington, KY 40503
859-276-0414 859-276-3765
Baptist Health Medical Group Hematology & Oncology
107 Diagnostic Drive
Frankfort, KY 40601
859-276-0414 859-276-3765


Medical School

University of Louisville School of Medicine


IU Health Methodist Hospital


Ohio State University


IU Health Methodist Hospital

Board Certifications

Medical Oncology

American Board of Internal Medicine

Hospital Affiliations

  • Baptist Health Richmond
  • Baptist Health Lexington

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.


Patient Experience Ratings

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Overall Rating
4.9 out of 5 (219 Ratings)
Review Categories
Patient Comments


  • Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8

    GI005: Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

    Trial Details
  • Colorectal Cancer

    NRG-GI004: This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places

    Trial Details
  • Colorectal Neoplasms (WIRB-22-0108)

    Mountaineer: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer

    Trial Details